Injecting RD06-03 CART cells to treat relapsed or refractory B-lymphoblastic leukemia

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study investigates the safety and efficacy of RD06-03 CART cell injections in patients with relapsed or refractory acute B-lymphoblastic leukemia (B-ALL). It includes a dose escalation phase to evaluate dose-limiting toxicity (DLT) followed by an efficacy exploration phase lasting up to one year. After assessing safety, researchers may expand the number of cases in specific dose groups based on treatment responses, with a maximum of 12 cases allowed. The study aims to provide insights into the potential benefits of this innovative treatment approach.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Aged ≥3 and ≤70 years, gender and race unrestricted.
* Bone marrow examination confirms the diagnosis of acute B-cell lymphoblastic leukemia (B-ALL) and meets one of the following conditions:

Relapsed B-ALL: ① Relapse within 12 months after the first remission; or ② Relapse after salvage chemotherapy in first-line/multi-line treatment; or ③ Relapse after autologous or allogeneic hematopoietic stem cell transplantation; Refractory B-ALL: ① Failure to achieve complete remission after 2 cycles of standardized induction chemotherapy; or ② Failure to achieve complete remission after salvage chemotherapy in first-line/multi-line treatment;

* Ph+ALL subjects are eligible if they meet one of the following criteria: ① Relapse or refractory after receiving at least 2 tyrosine kinase inhibitors (TKIs) treatments; if accompanied by TKI-resistant mutations such as T315I/A, V299L, F317L/V/I/C, G250E, Y253H, E255K/V, F359V/C/I, subjects are not required to receive at least two TKI treatments; or ② Unable to tolerate TKI treatment; or ③ Contraindications to TKI treatment.
* The proportion of bone marrow blasts during the screening period is ≥5% (morphological).Expression of CD19 on bone marrow or peripheral blood tumor cells is detected during the screening period.
* Organ function and laboratory tests meet the following criteria:

Serum total bilirubin \<2× upper limit of normal (ULN), serum ALT and AST both \<3× ULN, serum creatinine \<1.5× ULN; Coagulation function: International normalized ratio (INR) ≤1.5× ULN, or prothrombin time (PT) ≤1.5× ULN; Transthoracic echocardiogram shows left ventricular ejection fraction (LVEF) ≥50%; Resting oxygen saturation (SpO2) ≥92% in ambient air; Estimated survival period of more than 3 months;

* ECOG score 0-2;
* Fertile women must agree to use highly effective contraception from at least 28 days before leukapheresis to 6 months after CAR-T cell infusion. Their partners, fertile men, must agree to use effective barrier contraception from the start of leukapheresis to 6 months after CAR-T cell infusion, and should not donate semen or sperm during the entire trial period.

Exclusion Criteria:

* Suffering from genetic syndromes such as Fanconi anemia, Kostmann syndrome, Shwachman syndrome, or any other known bone marrow failure syndromes;
* History of allergy to any component of the cellular product;
* Presence of active central nervous system leukemia (CNSL) at screening;
* Patients with purely extramedullary relapse;
* Received allogeneic hematopoietic stem cell transplantation (HSCT) within 3 months before screening or experienced grade II to IV active graft-versus-host disease (GVHD) within 4 weeks before infusion;
* Significant cardiovascular dysfunction within 12 months before screening, including but not limited to: New York Heart Association (NYHA) class III or IV heart failure, myocardial infarction, unstable angina, uncontrolled or symptomatic atrial arrhythmias, any ventricular arrhythmias.

Presence or suspicion of uncontrollable active infection requiring intravenous therapy (excluding simple urinary tract infections, bacterial pharyngitis);

* Subjects with a history of other primary cancers, excluding the following:

Non-melanoma skin cancers such as basal cell carcinoma that have been cured by resection; Cervical carcinoma in situ, localized prostate cancer, ductal carcinoma in situ with disease-free survival ≥2 years after adequate treatment;

* Subjects with autoimmune diseases requiring treatment, immunodeficiency, or requiring immunosuppressive therapy;
* Received live attenuated vaccines within 4 weeks before screening, or planned to receive live attenuated vaccines during the study.

Where it's running

• Anhui Provincial Hospital
  Hefei, Anhui, China Recruiting
• Union Hospital Tongji Medical College Huazhong University of Science and Technology
  Wuhan, Hubei, China Recruiting

Study contacts

• Principal investigator: Xiaoyu Zhu, phd — Anhui Provincial Hospital
• Study coordinator: Xiaoyu Zhu, phd
• Email: xiaoyuz@ustc.edu.cn
• Phone: +86 15255456091

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Virtual buddy movement program to improve motor and social skills in children in remission from leukemia

  This 12-week program will test whether virtual buddy-led movement therapy helps children aged 5–12 in remission from precursor cell lymphoblastic leukemia improve motor skills and social interaction.

  Recruiting Comenius University · Bratislava · NCT07522905

• Electronic mindfulness-based music therapy for patients receiving stem cell transplantation

  This trial tests an eHealth mindfulness-based music therapy to see if it improves quality of life and reduces symptoms for adults undergoing stem cell transplantation.

  Recruiting University of Miami · Miami, Florida · NCT07469592

• Phase I CAR T-cell therapy for relapsed or refractory acute lymphoblastic leukemia in children, adolescents, and young adults

  This phase I study will test two CAR T-cell approaches to see if they are safe and feasible for children and young adults with relapsed or refractory B-ALL or T-ALL.

  Recruiting Phase 1 Instituto de Investigación Hospital Universitario La Paz · Madrid, Madrid · NCT06709469

• Combining low-dose chemotherapy with immuno-targeted drugs for elderly patients with Ph-negative B-ALL

  This study is testing a new treatment that combines low-dose chemotherapy with targeted drugs to see if it can help older patients with a specific type of leukemia feel better and stay in remission longer.

  Recruiting Phase 2 Institute of Hematology & Blood Diseases Hospital, China · Tianjin, Tianjin Municipality · NCT06387121

• Non-intensive treatment for adults with Ph-negative acute lymphoblastic leukemia

  This study is testing a gentler treatment for adults with Ph-negative acute lymphoblastic leukemia who are in remission but still have some cancer cells, to see if it can help them avoid more intense treatments.

  Recruiting National Research Center for Hematology, Russia · Moscow · NCT06237192

• Combining a pediatric treatment approach with Venetoclax for young and adult patients with a specific type of leukemia

  This study is testing a new treatment plan that combines a pediatric approach with Venetoclax to see if it helps teenagers and adults with a specific type of leukemia achieve better recovery and reduce the chance of relapse.

  Recruiting Phase 2 Institute of Hematology & Blood Diseases Hospital, China · Tianjin · NCT05660473

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.